Replimune Group, INC 10-Q quarterly reports

Replimune Group, Inc. reported increased net losses and R&D expenses in its latest quarterly filing, while navigating a resubmitted BLA for RP1 and extending its debt maturity.

Replimune Group, Inc. reported increased net losses and significant R&D expenses in its latest quarterly filing, while navigating an FDA Complete Response Letter for its lead candidate RP1 and facing multiple legal and regulatory investigations.

Replimune Group, Inc. announced a Complete Response Letter from the FDA for its lead cancer immunotherapy, RP1, signaling significant delays and potential strategic shifts.

Replimune Group announces its financial results for the quarter ended December 31, 2024, and provides an update on its clinical programs, including the FDA's acceptance and priority review of the BLA for RP1 in combination with nivolumab.

Replimune Group, Inc. announces positive results from its IGNYTE trial and progress towards a BLA submission for RP1 in anti-PD1 failed melanoma.

Replimune Group reports a net loss of $53.8 million for the first quarter of fiscal year 2025, while advancing its oncolytic immunotherapy pipeline.

Replimune Group's Q3 2024 report details financial results, clinical trial updates, and strategic shifts in their oncolytic immunotherapy programs.